收费全文 | 5043篇 |
免费 | 671篇 |
国内免费 | 137篇 |
耳鼻咽喉 | 24篇 |
儿科学 | 16篇 |
妇产科学 | 51篇 |
基础医学 | 180篇 |
口腔科学 | 19篇 |
临床医学 | 231篇 |
内科学 | 156篇 |
皮肤病学 | 15篇 |
神经病学 | 51篇 |
特种医学 | 119篇 |
外国民族医学 | 1篇 |
外科学 | 217篇 |
综合类 | 711篇 |
预防医学 | 126篇 |
眼科学 | 3428篇 |
药学 | 138篇 |
中国医学 | 91篇 |
肿瘤学 | 277篇 |
2024年 | 51篇 |
2023年 | 202篇 |
2022年 | 211篇 |
2021年 | 274篇 |
2020年 | 222篇 |
2019年 | 194篇 |
2018年 | 181篇 |
2017年 | 196篇 |
2016年 | 213篇 |
2015年 | 210篇 |
2014年 | 267篇 |
2013年 | 262篇 |
2012年 | 302篇 |
2011年 | 308篇 |
2010年 | 273篇 |
2009年 | 258篇 |
2008年 | 286篇 |
2007年 | 297篇 |
2006年 | 296篇 |
2005年 | 267篇 |
2004年 | 200篇 |
2003年 | 163篇 |
2002年 | 134篇 |
2001年 | 129篇 |
2000年 | 89篇 |
1999年 | 56篇 |
1998年 | 40篇 |
1997年 | 40篇 |
1996年 | 31篇 |
1995年 | 27篇 |
1994年 | 24篇 |
1993年 | 23篇 |
1992年 | 13篇 |
1991年 | 7篇 |
1990年 | 12篇 |
1989年 | 10篇 |
1988年 | 12篇 |
1987年 | 4篇 |
1986年 | 7篇 |
1985年 | 14篇 |
1984年 | 7篇 |
1983年 | 10篇 |
1982年 | 11篇 |
1981年 | 7篇 |
1980年 | 5篇 |
1979年 | 1篇 |
1978年 | 3篇 |
1977年 | 1篇 |
1976年 | 1篇 |
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献Areas covered: This review was written after detailed search in PubMed, EMBASE, ISI web, SciELO, Scopus, and Cochrane Central Register databases (from 1970 to 2019). It summarized the reported ophthalmologic adverse effects of the currently available AEDs; their risks and possible pathogenic mechanisms. They include ocular motility dysfunctions, retinopathy, maculopathy, glaucoma, myopia, optic neuropathy, and impaired retinal vascular autoregulation. In general, ophthalmo-neuro- or retino-toxic adverse effects of AEDs are classified as type A (dose-dependent), type B (host-dependent or idiosyncratic) or type C which is due to the cumulative effect from long-term use.
Expert opinion: Ocular adverse effects of AEDs are rarely reviewed although some are frequent or may result in permanent blindness. Increasing knowledge of their incidence and improving understanding of their risks and pathogenic mechanisms are crucial for monitoring, prevention, and management of patients’ at risk. 相似文献
Methods and Results: This case-control association study contained 1673 samples, including 869 ophthalmic patients and 804 controls. Twelve tag SNPs have been selected from the MYP10 and MYP15 loci and genotyped by SNaPshot method. Among 12 SNPs, rs4840437 and rs6989782 in TNKS gene were found significant association with HM. Carriers of rs4840437G allele and rs4840437GG genotype created a low risk of high myopia (P = .036, OR = 0.81, 95%CI = 0.71–0.93; P = .016, OR = 0.73, 95%CI = 0.56–0.96; respectively). Carriers of rs6989782T allele and rs6989782TT+CT genotype also had a decreased risk of high myopia (P = .048, OR = 0.82, 95%CI = 0.71–0.94; P = .006, OR = 0.74, 95%CI = 0.59–0.92; respectively). Other 10 SNPs displaced nonsignificant association with HM. Additionally, the risk haplotype AC and the protective haplotype GT, generated by two SNPs in TNKS, were considerably more likely to be association with HM (for AC, P = .002 and OR = 1.26; for GT, P = .027 and OR = 0.84).
Conclusions: Our results demonstrated that some heritable variants in the TNKS gene are associated with HM in the Han population. The possible functions of TNKS in the development and pathogenesis of hereditary high myopia still require further researches to identify. 相似文献